RESUMO
BACKGROUND: Insulin resistance promotes liver disease progression and may be associated with a lower response rate in treated hepatitis C virus (HCV) infected patients. n-3 polyunsaturated fatty acid (PUFA) supplementation may reduce insulin resistance. The present study aimed to evaluate the effect of n-3 PUFA supplementation on insulin resistance in these patients. METHODS: In a randomised, double-blind clinical trial, 154 patients were screened. After applying inclusion criteria, 52 patients [homeostasis model assessment index of insulin resistance (HOMA-IR ≥2.5)] were randomly divided into two groups: n-3 PUFA (n = 25/6000 mg day(-1) of fish oil) or control (n = 27/6000 mg day(-1) of soybean oil). Both groups were supplemented for 12 weeks and underwent monthly nutritional consultation. Biochemical tests were performed at baseline and after intervention. Statistical analysis was performed using the Wilcoxon Mann-Whitney test for comparisons and the Wilcoxon test for paired data. Statistical package r, version 3.02 (The R Project for Statistical Computing) was used and P < 0.05 (two-tailed) was considered statistically significant. RESULTS: Comparisons between groups showed that n-3 PUFA supplementation was more effective than the control for reducing HOMA-IR (P = 0.015) and serum insulin (P = 0.016). The n-3 PUFA group not only showed a significant reduction in HOMA-IR 3.8 (3.2-5.0) versus 2.4 (1.8-3.3) (P = 0.002); serum insulin 17.1 (13.8-20.6) µIU mL(-1) versus 10.9 (8.6-14.6) µIU mL(-1) (P = 0.001); and glycated haemoglobin 5.4% (5.0-5.7%) versus 5.1% (4.8-5.6%) (P = 0.011), but also presented an increase in interleukin-1 97.5 (0.0-199.8) pg mL(-1) versus 192.4 (102.2-266.8) pg mL(-1) (P = 0.003) and tumour necrosis factor 121.2 (0.0-171.3) pg mL(-1) versus 185.7 (98.0-246.9) pg mL(-1) (P = 0.003). CONCLUSIONS: n-3 PUFA supplementation reduces insulin resistance in genotype 1 HCV infected patients.
Assuntos
Ácidos Graxos Ômega-3/administração & dosagem , Hepatite C Crônica/tratamento farmacológico , Resistência à Insulina , Adolescente , Adulto , Idoso , Índice de Massa Corporal , Suplementos Nutricionais , Fígado Gorduroso/complicações , Feminino , Óleos de Peixe/administração & dosagem , Genótipo , Hepatite C Crônica/sangue , Hepatite C Crônica/complicações , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: The present study aimed to evaluate the impact of animal and vegetable protein supplementation on health-related quality of life (HRQL) in patients with hepatitis C virus (HCV) and to investigate clinical and nutritional variables related to quality of life in these patients. METHODS: One hundred and forty patients infected with HCV were randomly assigned to one of two groups: the Soy Group (SG; n = 72), where patients received a soy supplement diet and the Casein Group (CG; n = 68), where patients received casein as a supplement. Anthropometric, biochemical and clinical assessments were performed in all patients, and the Short-Form Health Survey was applied at baseline and 12 weeks after study initiation. RESULTS: Before supplementation, poor HRQL scores were associated with female sex (P = 0.004) and advanced fibrosis (F3/F4; P = 0.04). Reduced HRQL scores were correlated with age (r = -0.263; P = 0.002), serum albumin levels (r = 0.245; P = 0.004), lean mass (r = 0.301; P < 0.0001) and body fat percentage (r = -0.262; P = 0.002). After 12 weeks of intervention, patients in both supplementation groups showed significantly increased HRQL scores, with no difference being observed between the SG and the CG. CONCLUSIONS: Nutritional therapy with either soybean or casein supplementation improved quality of life in patients infected with HCV. Quality of life was influenced by anthropometric, biochemical, clinical and sociodemographic factors in patients with HCV before nutritional supplementation.
Assuntos
Caseínas/uso terapêutico , Proteínas Alimentares/uso terapêutico , Suplementos Nutricionais , Hepacivirus , Hepatite C Crônica/tratamento farmacológico , Qualidade de Vida , Proteínas de Soja/uso terapêutico , Tecido Adiposo/metabolismo , Adulto , Fatores Etários , Composição Corporal , Compartimentos de Líquidos Corporais/metabolismo , Caseínas/farmacologia , Proteínas Alimentares/farmacologia , Fibrose , Hepatite C Crônica/metabolismo , Hepatite C Crônica/patologia , Hepatite C Crônica/virologia , Humanos , Pessoa de Meia-Idade , Albumina Sérica/metabolismo , Fatores Sexuais , Proteínas de Soja/farmacologiaRESUMO
The performance of an enzyme-linked immunosorbent assay (ELISA), an indirect fluorescent antibody test (IFAT) and a rapid conglutination test (RCT) for the detection of antibodies against Babesia bovis, was evaluated with 462 cattle sera from Bahia State; Brazil. The results showed a concordance of 96.6% between the ELISA and IFAT, 90.5% between the ELISA and RCT, and 91.8% between the IFAT and RCT. Although the prevalence rates determined by ELISA (97.2%) and IFAT (96.8%) were higher than that indicated by the RCT (92.9%), performances of the three serological tests were very similar and characterized the region studied as enzootically stable to B. bovis.